LGND - Company ID 0000886163
The table below shows LIGAND PHARMACEUTICALS INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $51.72M | $115.46M | $47.63M | $45.33M | $51.81M | $41.53M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.15M | $21.02M | $6.57M | $50.09M | $5.67M | $5.35M |
LIGAND PHARMACEUTICALS INC reported annual revenue of $268.09M for fiscal year 2025. That is up 60.4% from $167.13M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $108.97M (FY 2016) to $268.09M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $20.84M |
| $28.45M |
| $20.18M |
| $18.80M |
| $24.48M |
| $17.62M |
| Operating income | $17.37M | $54.93M | $8.44M | -$36.22M | $3.14M | -$19.10M |
| Income tax | -$10.91M | $23.86M | $6.38M | -$7.73M | $833.00K | -$13.48M |
| Net income | -$13.35M | $117.27M | $4.85M | -$42.45M | -$7.17M | -$51.91M |
| EPS (diluted) | -$0.67 | $5.68 | $0.24 | -$2.21 | -$0.39 | -$2.88 |